CLINICAL TRIALS PROFILE FOR SKYRIZI

All Clinical Trials for SKYRIZI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02047110 ↗	BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)	Completed	Boehringer Ingelheim	Phase 2	2014-01-28	The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.
NCT02047110 ↗	BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)	Completed	AbbVie	Phase 2	2014-01-28	The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.
NCT02203851 ↗	Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis	Completed	Boehringer Ingelheim	Phase 2	2014-11-20	The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment. Additional study objectives were to further investigate the long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of risankizumab.
NCT02203851 ↗	Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis	Completed	AbbVie	Phase 2	2014-11-20	The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment. Additional study objectives were to further investigate the long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of risankizumab.
NCT02672852 ↗	BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment	Completed	Boehringer Ingelheim	Phase 3	2016-02-29	This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque psoriasis.
NCT02672852 ↗	BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment	Completed	AbbVie	Phase 3	2016-02-29	This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants with moderate to severe chronic plaque psoriasis.

Clinical Trial Conditions for SKYRIZI

Condition Name

Condition Name for SKYRIZI
Intervention	Trials
Psoriasis	15
Crohn's Disease	6
Healthy Volunteers	6
Arthritis, Psoriatic	2

Condition MeSH

Condition MeSH for SKYRIZI
Intervention	Trials
Psoriasis	18
Crohn Disease	7
Arthritis, Psoriatic	3
Arthritis	3

Clinical Trial Locations for SKYRIZI

Trials by Country

Trials by Country for SKYRIZI
Location	Trials
United States	402
Japan	102
Canada	72
Germany	72
Italy	58

Trials by US State

Trials by US State for SKYRIZI
Location	Trials
Illinois	23
California	23
Texas	22
Florida	22
New York	17

Clinical Trial Progress for SKYRIZI

Clinical Trial Phase

Clinical Trial Phase for SKYRIZI
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	20
Phase 2	5

Clinical Trial Status

Clinical Trial Status for SKYRIZI
Clinical Trial Phase	Trials
Completed	18
Recruiting	11
Active, not recruiting	3

Clinical Trial Sponsors for SKYRIZI

Sponsor Name

Sponsor Name for SKYRIZI
Sponsor	Trials
AbbVie	34
Boehringer Ingelheim	7
Istituto Clinico Humanitas	1

Sponsor Type

Sponsor Type for SKYRIZI
Sponsor	Trials
Industry	42
Other	7